MedTrace Logo

Mold Allergy in Austria: Clinical Relevance of Alternaria Alternata and Related Species

NCT05101733 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2022-04-12

No results posted yet for this study

Summary

Mold allergies are becoming increasingly important among the population. Increasing amounts of fungal spores are analyzed in air-samples because of urbanization, industrialization of food products and climate change. Mold also grows indoor and hence lead to additional health complaints.

Alternaria alternata, and its only major allergen Alt a 1, is the most important fungus for allergy sufferers. Alternaria alternata can not only cause allergic symptoms but can also cause intensified asthmatic symptoms.

Besides Alternaria alternata, there are over 700 other species of the genus Alternaria. The influence of these other species on allergic symptoms is poorly understood.

Furthermore, prevalence and incidence of an allergy to Alternaria alternata among the Austrian population is not known. Estimates range between 1-5% among the Austrian population.

This study aims to further investigate the incidence and characteristics of an allergy to Alternaria in Austria. This will be investigated with the help of participants (50 Alternaria allergy sufferers and 20 non allergic participants), spore counts in Austria and crowd-sourced symptom data.

Conditions

  • Fungal Allergy
  • Allergy

Interventions

DIAGNOSTIC_TEST

Nasal provocation

Nasal provocation with Alternaria alternata extract. Changes in nasal mucosa are measured with a rhinomanometry device

DIAGNOSTIC_TEST

Skin-Prick Test

Skin-Prick-Test is administered to determine an allergy against Alternaria

DIAGNOSTIC_TEST

Blood draw

For further analysis

DIAGNOSTIC_TEST

Collection of nasal secretion

Allergy sufferers: After nasal provocation Non-allergics: After administration of isotonic nasal spray

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Erika Jensen-Jarolim, Univ.-Prof. Dr. · Department of Pathophysiology and Allergy Research

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-14
Primary Completion
2023-07-31
Completion
2023-07-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05101733 on ClinicalTrials.gov